Enlivex receives authorization for initiation of Phase I trial of Allocetra

Enlivex Therapeutics (ENLV) announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra for injection into the temporomandibular joint, TMJ, in patients suffering from TMJ osteoarthritis. The Phase I trial aims to recruit six patients who have shown insufficient response to conventional treatments for TMJ osteoarthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and efficacy endpoints will assess changes from baseline in TMJ pain, joint functionality, and other disease parameters for up to 12 months following administration of Allocetra.